DEFA14A: Enhabit to Go Private in $1.1B Kinderhook Acquisition

Enhabit, Inc., a national home health and hospice provider, has agreed to be acquired by Kinderhook Industries, LLC in an all-cash transaction valued at approximately $1.1 billion, with stockholders receiving $13.80 per share.

Summary

• Enhabit, Inc. will be acquired by Anchor Parent, LLC, an affiliate of Kinderhook Industries, LLC, in an all-cash transaction.
• Enhabit stockholders will receive $13.80 in cash for each share of Company Common Stock.
• The total enterprise value of the acquisition is approximately $1.1 billion.
• The per-share consideration represents a premium of approximately 24.4% to Enhabit's closing stock price on February 20, 2026, and a 33.8% premium to its 60-day volume-weighted average share price for the period ended February 20, 2026.
• Enhabit's Board of Directors unanimously approved the Merger Agreement.
• Upon completion, Enhabit will become a wholly-owned subsidiary of Parent, and its common stock will no longer be listed on the New York Stock Exchange.
• Certain Enhabit executive officers have entered into customary voting and support agreements to vote in favor of the transaction.
• Kinderhook has secured committed debt and equity financing, totaling $688 million from the Equity Investor, sufficient to fund the purchase price and related expenses.
• Enhabit will not conduct an earnings conference call or webcast, nor issue financial guidance for 2026, due to the announced transaction.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development for Enhabit shareholders, offering a substantial premium and liquidity through an all-cash transaction, reflecting strong confidence from the acquiring private equity firm.

Positives

• Stockholders will receive a significant premium of approximately 24.4% over the closing stock price on February 20, 2026, and 33.8% over the 60-day volume-weighted average share price.
• The all-cash nature of the transaction provides certainty and immediate liquidity for Enhabit stockholders.
• The unanimous approval by Enhabit's Board of Directors indicates strong confidence that the transaction maximizes value for stockholders.
• Under Kinderhook's private ownership, Enhabit expects to benefit from additional resources and expertise to support long-term investments in its people, clinical excellence, and innovation, free from short-term public market pressures.
• Kinderhook has secured committed financing for the transaction, reducing financing risk for the deal's completion.

Negatives

• Enhabit will become a private company, leading to the delisting of its common stock from the New York Stock Exchange and removing public market access for investors.
• The company will not issue financial guidance for 2026 or conduct a Q4 2025 earnings call, which limits immediate future financial transparency for investors.
• The Merger Agreement includes substantial termination fees: Enhabit would pay approximately $24.5 million to Parent under specified circumstances, and Parent would pay approximately $44.6 million to Enhabit under others.
• Certain restrictions during the pendency of the proposed merger may impact Enhabit's ability to pursue specific business opportunities or strategic transactions.

Risks

• The proposed merger may not be completed in a timely manner or at all, which could adversely affect Enhabit's business and the price of its common stock.
• Failure to satisfy any of the conditions to the consummation of the merger, including the receipt of certain regulatory approvals.
• Failure to obtain the required Enhabit stockholder approval.
• The occurrence of any fact, event, change, development, or circumstance that could give rise to the termination of the Merger Agreement, potentially requiring Enhabit to pay a termination fee.
• The effect of the announcement or pendency of the proposed merger on Enhabit's business relationships, operating results, and business generally.
• Risks that the proposed merger disrupts Enhabit's current plans and operations.
• Enhabit's ability to retain and hire key personnel and maintain relationships with key business partners and customers, and others with whom it does business, in light of the proposed merger.
• Risks related to the diversion of management's attention from Enhabit's ongoing business operations.
• Unexpected costs, charges, or expenses resulting from the proposed merger.
• The ability of Parent (Kinderhook) to obtain financing for the proposed merger.
• Potential litigation relating to the proposed merger that could be instituted against the parties to the Merger Agreement or their respective directors, managers, or officers, including the effects of any outcomes related thereto.
• Continued availability of capital and financing.
• Certain restrictions during the pendency of the proposed merger that may impact Enhabit's ability to pursue certain business opportunities or strategic transactions.
• Other risks described in Enhabit's filings with the SEC, such as those in its Annual Report on Form 10-K filed on March 6, 2025, and subsequent filings.

Future Outlook

Enhabit will cease to be a publicly traded company and will no longer issue financial guidance for 2026. Under Kinderhook's ownership, Enhabit expects to benefit from additional resources and expertise to support long-term investments in its people, clinical excellence, and innovation, focusing on expanding access to home health and hospice services for families and their communities.

Management Comments

• Jeffrey W. Bolton, Chairman of Enhabit's Board of Directors, stated that the Board is confident this transaction maximizes value for stockholders and is in their best interest, following a thorough evaluation and extensive deliberations.
• Barb Jacobsmeyer, President and Chief Executive Officer of Enhabit, commented that the agreement is a 'terrific outcome' for stockholders, clinicians, caregivers, patients, and their families, and that Kinderhook's ownership will support long-term investments without the short-term pressures of public markets.
• Chris Michalik, Managing Director at Kinderhook, expressed admiration for Enhabit's leadership, patient-centric culture, and strong market position, highlighting Kinderhook's 20-year track record of investing in industry-leading companies and partnering with management teams.
• Matt Bubis, Managing Director at Kinderhook, emphasized that the investment is about backing a great organization and providing it with the room and resources to succeed for the long run, thanks to its exceptional care teams and strong leadership.

Industry Context

StockSavvy.ai notes that the acquisition of Enhabit by Kinderhook Industries reflects a broader trend in the healthcare services sector, particularly in home-based care, where private equity firms are increasingly investing. This trend is driven by the aging population, preference for in-home care, and the potential for operational efficiencies and long-term growth away from public market scrutiny. Kinderhook's stated strategy of providing long-term capital and practical support aligns with private equity's typical approach to fostering growth in specialized healthcare providers.

Comparison to Industry Standards

• The premium offered (24.4% over closing price, 33.8% over 60-day VWAP) is generally considered attractive for an all-cash acquisition in the healthcare services sector, often exceeding typical premiums seen in public-to-private transactions.
• Kinderhook's 20-year track record of investing in industry-leading companies and partnering with management teams is a strong indicator of its expertise in the middle-market private equity space, comparable to other established healthcare-focused private equity firms like Welsh, Carson, Anderson & Stowe or Advent International, which also target growth-oriented companies.
• The total enterprise value of approximately $1.1 billion for a national home health and hospice provider like Enhabit (249 home health, 117 hospice locations across 34 states) suggests a valuation consistent with market multiples for established, scaled players in the fragmented home-based care industry, where consolidation is a key theme.

Management Changes

Corporate Governance

Legal Proceedings

• Potential litigation relating to the proposed merger that could be instituted against the parties to the Merger Agreement or their respective directors, managers, or officers.
• Risks related to stockholders exercising statutory rights of appraisal under Section 262 of the Delaware General Corporation Law.

Related Party Transactions

• Certain Enhabit stockholders (collectively, the Supporting Stockholders), holding over 2.0% of the voting power, entered into voting and support agreements with Parent and Merger Sub to vote in favor of the merger.
• The Tax Matters Agreement entered into by and between Encompass Health Corporation and Enhabit, Inc., dated as of June 30, 2022, is an existing related party agreement.

Stakeholder Impact

• Shareholders: Will receive $13.80 per share in cash, representing a significant premium, providing immediate liquidity and value realization.
• Clinicians/Caregivers: Management states the agreement is a 'terrific outcome' and that Kinderhook's ownership will support long-term investments in people, clinical excellence, and innovation.
• Patients/Families: Management expects expanded access to critical home health and hospice services and better outcomes.
• Employees: The agreement includes provisions for continuing employees' base salary, cash incentive opportunities, and severance benefits for at least one year post-merger, comparable to pre-merger terms (excluding certain benefits).
• Company Management: Will benefit from additional resources and expertise, focusing on long-term growth without public market pressures.

Next Steps

• Enhabit is expected to announce a special meeting of stockholders as soon as practicable to obtain stockholder approval of the proposed transaction.
• Enhabit intends to file relevant materials with the SEC, including a proxy statement in preliminary and definitive form.
• The acquisition is expected to close in the second quarter of 2026, subject to the receipt of Enhabit stockholder approval and regulatory approvals, and the satisfaction of other customary closing conditions.
• Enhabit's fourth quarter and fiscal year 2025 earnings release is expected on March 4, 2026.
• Parent and Merger Sub will file all required notices, reports, and other documents under the HSR Act within 20 Business Days after the agreement date and use reasonable best efforts to secure expiration or termination of waiting periods.
• Parent will lead discussions with all Governmental Authorities and determine strategy related to obtaining clearances and approvals.

Key Dates

Recommendation

The all-cash acquisition at a substantial premium (24.4% over recent closing price, 33.8% over 60-day VWAP) offers immediate and certain value to shareholders. Given the unanimous board approval and committed financing, the likelihood of deal completion is high, making it a compelling opportunity for investors to capture the premium.

Keywords

Enhabit, Kinderhook Industries, Merger, Acquisition, Home Health, Hospice, Private Equity, Delisting, Stockholder Approval, Regulatory Approval, Cash Transaction, Healthcare Services, DEFA14A